GNI Group Limited operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares GNI Group Limited with three other
companies in this sector in Japan:
Japan Tissue Engineering Company Limited
sales of 1.43 billion Japanese Yen [US$12.75 million]
of which 93%
was Regenerative Medicine Products Business),
SanBio Co Ltd
(1.17 billion Japanese Yen [US$10.47 million]
of which 100%
was Commercial Physical Research), and
PhoenixBio Co Ltd
(1.22 billion Japanese Yen [US$10.84 million]
GNI Group Limited reported sales of ¥1.31 billion (US$11.64 million)
December of 2016.
increase of 28.6%
versus 2015, when the company's sales were ¥1.02 billion.
Sales at GNI Group Limited have increased during each of the previous five years
(and since 2011, sales have increased a total of 1,347%).
Sales of Operating Segment -China saw an increase
29.6% in 2016, from
¥993.23 million to ¥1.29 billion.
Not all segments of GNI Group Limited experienced an increase in sales in 2016:
sales of Operating Segment -Japan fell 17.8% to ¥19.26 million.
(However, this segment's sales were only a very small portion of the company's overall sales).